Eptinezumab Anti-CGRP monoclonal antibody Treatment of migraine

被引：0

作者：

Lu, Lingyun ^{[1
]}

Liu, Meijun ^{[2
]}

Hu, Songshan ^{[1
]}

Liu, Yao ^{[3
]}

Yang, Dongdong ^{[2
]}

Hong, Peiwei ^{[4
]}

机构：

[1] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China

[2] Chengdu Univ Tradit Chinese Med, Affiliated Hosp 1, Chengdu, Sichuan, Peoples R China

[3] Xindu Hosp Tradit Chinese Med, Chengdu, Sichuan, Peoples R China

[4] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Sichuan, Peoples R China

来源：

DRUGS OF THE FUTURE | 2017年 / 42卷 / 10期

关键词：

Eptinezumab; ALD-403; Anti-CGRP; Antimigraine drugs; GENE-RELATED PEPTIDE; RANDOMIZED CONTROLLED-TRIAL; RECEPTOR ANTAGONIST; DOUBLE-BLIND; PREVENTIVE TREATMENT; EPISODIC MIGRAINE; TELCAGEPANT; EFFICACY; SAFETY; TOLERABILITY;

D O I：

10.1358/dof.2017.042.10.2701433

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Eptinezumab (ALD-403) is a genetically engineered, humanized, desialylated anti-calcitonin gene-related peptide (CGRP) IgG1 monoclonal antibody that selectively binds to both a and beta forms of human CGRP, which is a promising therapeutic target for migraine. Pharmacokinetic data indicated that monthly dosing of an intravenous eptinezumab infusion could maintain bioactive levels and blood concentration for a long time. Phase I and II studies evaluating the safety and efficacy of eptinezumab in episodic and chronic migraine were completed with encouraging results, and there are currently three large phase III studies ongoing. This review summarizes the clinical trials already conducted or ongoing and the initial findings regarding the safety and efficacy of eptinezumab for the treatment of migraine.

引用

页码：609 / 615

页数：7

共 43 条

[1] Serotonin and CGRP in Migraine [J].

Aggarwal, Milan ;

Puri, Veena ;

Puri, Sanjeev .

ANNALS OF NEUROSCIENCES, 2012, 19 (02) :88-94

[2] ALTERNATIVE RNA PROCESSING IN CALCITONIN GENE-EXPRESSION GENERATES MESSENGER-RNAS ENCODING DIFFERENT POLYPEPTIDE PRODUCTS [J].

AMARA, SG ;

JONAS, V ;

ROSENFELD, MG ;

ONG, ES ;

EVANS, RM .

NATURE, 1982, 298 (5871) :240-244

[3]

[Anonymous], ROB DEV PIP

[4] Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development [J].

Archbold, Julia K. ;

Flanagan, Jack U. ;

Watkins, Harriet A. ;

Gingell, Joseph J. ;

Hay, Debbie L. .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (10) :591-600

[5] Calcitonin and calcitonin receptor-like receptors: common themes with family B GPCRs? [J].

Barwell, James ;

Gingell, Joseph J. ;

Watkins, Harriet A. ;

Archbold, Julia K. ;

Poyner, David R. ;

Hay, Debbie L. .

BRITISH JOURNAL OF PHARMACOLOGY, 2012, 166 (01) :51-65

[6] The International Classification of Headache Disorders, 3rd edition (beta version) [J].

Bes, Andre ;

Kunkel, Robert ;

Lance, James W. ;

Nappi, Giuseppe ;

Pfaffenrath, Volker ;

Rose, Frank Clifford ;

Schoenberg, Bruce S. ;

Soyka, Dieter ;

Tfelt-Hansen, Peer ;

Welch, K. Michael A. ;

Wilkinson, Marica ;

Olesen, Jes ;

Bousser, Marie-Germaine ;

Diener, Hans-Christoph ;

Dodick, David ;

First, Michael ;

Goadsby, Peter J. ;

Goebel, Hartmut ;

Lainez, Miguel J. A. ;

Lance, James W. ;

Lipton, Richard B. ;

Nappi, Giuseppe ;

Sakai, Fumihiko ;

Schoenen, Jean ;

Silberstein, Stephen D. ;

Steiner, Timothy J. ;

Olesen, Jes ;

Bendtsen, Lars ;

Dodick, David ;

Ducros, Anne ;

Evers, Stefan ;

First, Michael ;

Goadsby, Peter J. ;

Hershey, Andrew ;

Katsarava, Zaza ;

Levin, Morris ;

Pascual, Julio ;

Russell, Michael B. ;

Schwedt, Todd ;

Steiner, Timothy J. ;

Tassorelli, Cristina ;

Terwindt, Gisela M. ;

Vincent, Maurice ;

Wang, Shuu-Jiun ;

Olesen, J. ;

Evers, S. ;

Charles, A. ;

Hershey, A. ;

Lipton, R. ;

First, M. .

CEPHALALGIA, 2013, 33 (09) :629-808

[7] Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study [J].

Bigal, Marcelo E. ;

Dodick, David W. ;

Rapoport, Alan M. ;

Silberstein, Stephen D. ;

Ma, Yuju ;

Yang, Ronghua ;

Loupe, Pippa S. ;

Burstein, Rami ;

Newman, Lawrence C. ;

Lipton, Richard B. .

LANCET NEUROLOGY, 2015, 14 (11) :1081-1090

[8] Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study [J].

Bigal, Marcelo E. ;

Edvinsson, Lars ;

Rapoport, Alan M. ;

Lipton, Richard B. ;

Spierings, Egilius L. H. ;

Diener, Hans-Christoph ;

Burstein, Rami ;

Loupe, Pippa S. ;

Ma, Yuju ;

Yang, Ronghua ;

Silberstein, Stephen D. .

LANCET NEUROLOGY, 2015, 14 (11) :1091-1100

[9] Randomized, controlled trial of telcagepant for the acute treatment of migraine [J].

Connor, K. M. ;

Shapiro, R. E. ;

Diener, H. -C. ;

Lucas, S. ;

Kost, J. ;

Fan, X. ;

Fei, K. ;

Assaid, C. ;

Lines, C. ;

Ho, T. W. .

NEUROLOGY, 2009, 73 (12) :970-977

[10] Long-Term Tolerability of Telcagepant for Acute Treatment of Migraine in a Randomized Trial [J].

Connor, Kathryn M. ;

Aurora, Sheena K. ;

Loeys, Tom ;

Ashina, Messoud ;

Jones, Christopher ;

Giezek, Hilde ;

Massaad, Rachid ;

Williams-Diaz, Angela ;

Lines, Christopher ;

Ho, Tony W. .

HEADACHE, 2011, 51 (01) :73-84

← 1 2 3 4 5 →